Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 2

The Role of Islet GLP-1 in the Pathogenesis of Prediabetes

Mayo Clinic · NCT06967558

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 25–70 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Phase 2
Target enrollment
60
US sites recruiting
1
Study start
November 1, 2025
Record last updated
December 15, 2025

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

We recently demonstrated that blockade of Glucagon-Like Peptide-1's (GLP-1) receptor (GLP1R) results in changes in islet function without changes in circulating GLP-1. These effects are more pronounced in people with early type 2 diabetes (T2DM) in keeping with increased expression of PC-1/3 and GLP-1 that is observed in diabetic islets. However, its regulation is at present unknown. At present it is unknown if these abnormalities develop in prediabetes and whether they contribute to the phenotypes observed. In this experiment we will use blockade of GLP1R to probe the contribution of endogenous GLP-1 secretion to the regulation of fasting glucose and islet function in prediabetes.

Being studied: Exendin 9-39; Saline

Conditions: PreDiabetes

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • People with stable weight and no history of diabetes.
  • Fasting glucose \< 126 mg/dL
  • 2hr glucose after 75g OGTT \< 200 mg/dL

Exclusion Criteria

  • Age \< 25 or > 70 years (to avoid studying subjects who could have latent type 1 diabetes, or the effects of age extremes in subjects with normal or impaired fasting glucose).
  • HbA1c > 6.5%
  • Use of any glucose-lowering agents including metformin or sulfonylureas.
  • For female subjects: positive pregnancy test at the time of enrollment or study
  • History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.
  • Active systemic illness or malignancy.
  • Symptomatic macrovascular or microvascular disease.

Recruiting US locations

  • Mayo Clinic in Rochester

    Rochester, MN 55905

    Site contact: Amy O'Byrne · 507-255-8547 · OByrne.Amy14@mayo.edu

Study contacts (from the official record)

  • Adrian Vella, MD · 507-255-6515 · vella.adrian@mayo.edu
All diabetes studies in Minnesota →
The Role of Islet GLP-1 in the Pathogenesis of Prediabetes (NCT06967558) | Bored Studies